Proactive Investors - Run By Investors For Investors

Kazia Therapeutics substantial holder Willoughby Capital increases interest to 17.52%

Edison Investment Research has assigned an indicative valuation range of $84–135 million or $1.35–2.17 per share for Kazia.
Kazia Therapeutics substantial holder Willoughby Capital increases interest to 17.52%
Kazia shares held by Willoughby were previously held by Hishenk Pty Ltd

Kazia Therapeutics Ltd (ASX:KZA) substantial holder Hishenk Pty Ltd has increased its interest in the company from 17.4% to 17.52% after purchasing 55,000 shares on-market.

This comes after the holder reiterated its confidence in the biotechnology company’s oncology drug develoomet last week by increasing its share to 17.4% from 13.8%.

Due to a restructure, the Kazia shares are now held by Willoughby Capital Pty Ltd ATF Willoughby Capital Trust, an associated entity of Hishenk due to common directors and shareholders.


Kazia is developing GDC-0084 brain penetrant PI3K inhibitor GDC-0084 and a third generation benzopyran drug, Cantrixil.

Licensed from Genentech in October 2016, GDC-0084 is a novel targeted therapy that inhibits the PI3K pathway, important in many forms of cancer and activated in 85-90% of GBM cases.

Glioblastoma multiforme is the most common and aggressive form of primary brain cancer, with chemotherapy treatment temozolomide only effective in one-third of patients.

Furthermore, the median survival rate is 12-15 months from diagnosis, meaning there is demand in the market for superior treatments.

View full KZA profile View Profile

Kazia Therapeutics Ltd Timeline

Related Articles

technician's in a lab clean-room
March 12 2019
The Maryland company is seeing revenue surge through an expansion of contract manufacturing services, particularly in the area of CAR T-cell therapies
test tubes
April 16 2019
Summit Therapeutics' potential breakthrough targets C.difficile
Empty lab
September 19 2018
Management has made some tough decisions, cutting the cost base, since a disappointing first-half performance and expects the benefits to really kick in next year
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use